The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

Bibliography

• Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64(10):935-51
   PubMed Web of Science ®Google Scholar
• Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14(8):963-78
   PubMed Web of Science ®Google Scholar
• Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17(1):22-37
   PubMed Web of Science ®Google Scholar
• Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999;59(2):57-77
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8
   PubMed Web of Science ®Google Scholar
• Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001;13(Suppl 1):S29-33
   PubMed Web of Science ®Google Scholar
• Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors–overview and clinical implications. Aliment Pharmacol Ther 2004;20(Suppl 6):1-10
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305(19):1969-77
   PubMed Web of Science ®Google Scholar
• Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333(17):1106-10
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59(3):135-53
   PubMed Web of Science ®Google Scholar
• Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012;61(9):1340-54
   PubMed Web of Science ®Google Scholar
• Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009;58(9):1185-91
   PubMed Web of Science ®Google Scholar
• Savarino V, Savarino E, Parodi A, Dulbecco P. Functional heartburn and non-erosive reflux disease. Dig Dis 2007;25(3):172-4
   PubMed Web of Science ®Google Scholar
• Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54(5):710-17
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Marabotto E, et al. Overweight is a risk factor for both erosive and non-erosive reflux disease. Dig Liver Dis 2011;43(12):940-5
   PubMedGoogle Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-20
   PubMed Web of Science ®Google Scholar
• Savarino E, Tutuian R, Zentilin P, et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010;105(5):1053-61
   PubMed Web of Science ®Google Scholar
• Savarino E, Marabotto E, Zentilin P, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis 2011;43(7):542-7
   PubMedGoogle Scholar
• Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47(2):159-68
   PubMed Web of Science ®Google Scholar
• Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009;179(5):408-13
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Nacci A, Savarino E, et al. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol 2012;18(32):4363-70
   PubMed Web of Science ®Google Scholar
• Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005;54(4):449-54
   PubMed Web of Science ®Google Scholar
• Tutuian R, Mainie I, Agrawal A, et al. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest 2006;130(2):386-91
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis 2006;24(1-2):11-46
   PubMed Web of Science ®Google Scholar
• Kwon D, Chae JB, Park CW, et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung 2001;51(3):204-13
   PubMed Web of Science ®Google Scholar
• Kim EJ, Lee RK, Lee SM, Kim DY. General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung 2001;51(1):51-9
   PubMed Web of Science ®Google Scholar
• Kil BJ, Kim IW, Shin CY, et al. Comparison of IY81149 with omeprazole in rat reflux oesophagitis. J Auton Pharmacol 2000;20(5-6):291-6
   PubMedGoogle Scholar
• Goldwater R, Lee S, Chung G, et al. A phase I, randomized, parallel placebo-controlled safety, tolerance and pharmacokinetic study of multiple doses of IY-8119 in fasting male volunteers [abstract]. Clin Pharmacol Ther 1999;65:PI-35
   Google Scholar
• Periclou AP, Goldwater R, Lee SM, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000;68(3):304-11
   PubMed Web of Science ®Google Scholar
• Cho H, Choi MK, Cho DY, et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol 2012;52(7):976-84
   PubMed Web of Science ®Google Scholar
• Myung SW, Min HK, Jin C, et al. Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res 1999;22(2):189-93
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang W, Guo D, et al. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 2008;391(1-2):60-7
   PubMed Web of Science ®Google Scholar
• Zhou G, Shi S, Zhang W, et al. Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed Chromatogr 2010;24(10):1130-5
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95(1):2-8
   PubMed Web of Science ®Google Scholar
• Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica 2012;42(3):278-84
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11(9):773-9
   PubMedGoogle Scholar
• Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005;6(7):731-47
   PubMed Web of Science ®Google Scholar
• Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005;353(1-2):187-92
   PubMed Web of Science ®Google Scholar
• McColl KE, Kennerley P. Proton pump inhibitors–differences emerge in hepatic metabolism. Dig Liver Dis 2002;34(7):461-7
   PubMedGoogle Scholar
• Egan LJ, Murray JA. New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors. Dig Dis 2000;18(2):58-63
   PubMed Web of Science ®Google Scholar
• Du YQ, Guo WY, Zou DW, et al. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis 2012;13(2):113-19
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou L, Hu H, et al. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin 2012;28(1):101-9
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Mathot RA, Touw DJ, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008;65(5):752-60
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005;20(3):153-67
   PubMedGoogle Scholar
• Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008;47(1):1-6
   PubMed Web of Science ®Google Scholar
• Lindberg P, Keeling D, Fryklund J, et al. Review article: esomeprazole–enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003;17(4):481-8
   PubMed Web of Science ®Google Scholar
• Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15(10):1563-9
   PubMed Web of Science ®Google Scholar
• Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag 2007;3(3):363-79
   PubMedGoogle Scholar
• Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003;23(4):460-71
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98(12):2616-20
   PubMed Web of Science ®Google Scholar
• Cao S, Zhou G, Ou-Yang DS, et al. Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. Acta Pharmacol Sin 2012;33(8):1095-100
   PubMed Web of Science ®Google Scholar
• Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003;4(2):253-64
   PubMed Web of Science ®Google Scholar
• Zentilin P, Dulbecco P, Savarino E, et al. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review. Dig Liver Dis 2004;36(9):565-9
   PubMedGoogle Scholar
• Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005;50(10):1909-15
   PubMed Web of Science ®Google Scholar
• Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100(2):283-9
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53(9):2387-93
   PubMed Web of Science ®Google Scholar
• Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):59-67
   PubMed Web of Science ®Google Scholar
• Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33(1):118-24
   PubMed Web of Science ®Google Scholar
• Ho KY, Kuan A, Zano F, et al. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. J Gastroenterol 2009;44(7):697-707
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou L, Lin S, et al. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastroenterol 2011;45(4):322-9
   PubMed Web of Science ®Google Scholar